

08-03-01

#2 1631

O I P E

AUG 02 2001
PATENT & TRADEMARK OFFICE

Docket No. 708-4057

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Phyllis SHAPIRO

Group Art Unit: To Be Assigned

Serial No.: 09/865,759

Examiner: To Be Assigned

Filed: May 25, 2001

RECEIVED
AUG 09 2001
TECH CENTER 1600/2900

For: **Automated Method for Correcting Blood Analysis Parameter Results Affected by Interference from Exogenous Blood Substitutes in Whole Blood, Plasma, and Serum**

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

This Information Disclosure Statement is filed in accordance with 37 C.F.R. §§1.56, 1.97 and 1.98. The items listed on Form PTO-1449, a copy of which is enclosed, are made of record to assist the Patent and Trademark Office in its examination of this application. The Examiner is respectfully requested to fully consider the items and to independently ascertain their teaching.

1. For each of the following items listed on the enclosed copy of Form PTO-1449 that is not in the English language, an English language translation of that item or a portion thereof or a concise explanation of the relevance of that item is enclosed:

2. For each of the following items listed on the enclosed copy of Form PTO-1449 that is not in the English language, a concise explanation of the relevance of that item is incorporated in the specification of the above-identified application.
3. Any copy of the items listed on the enclosed copy of Form PTO-1449 that is not enclosed with this Information Disclosure Statement was previously cited by or submitted to the Patent and Trademark Office in application Serial No. _____, filed _____.

4. No fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with:

37 C.F.R. §1.97(b)(1), within three months of the filing date of a national application other than a CPA; or

37 C.F.R. §1.97(b)(2), within three months of the date of entry into the national stage as set forth in §1.491 in an international application; or

37 C.F.R. §1.97(b)(3), before the mailing date of a first Office action on the merits; or

37 C.F.R. §1.97(b)(4), before the mailing date of a first office action after the filing of an RCE under §1.114.

The Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. 13-4500., Order No. 708-4057. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

Respectfully submitted,
MORGAN & FINNEGAN, L.L.P.

Dated: August 2, 2001

By: Leslie Serunian
Leslie A. Serunian
Registration No. 35,353

Correspondence Address:

MORGAN & FINNEGAN, L.L.P.
345 Park Avenue
New York, NY 10154-0053
(212) 758-4800 Telephone
(212) 751-6849 Facsimile